Clacid SR, 500 mg 14 pcs
€1.00
Out of stock
(E-mail when Stock is available)
Clacid SR is an antibiotic of macrolide group. Clarithromycin inhibits protein synthesis in microbial cell by interacting with 50S ribosomal subunit of bacteria. It is highly active against a wide range of aerobic, anaerobic, Gram-positive and Gram-negative bacteria.
Clarithromycin has demonstrated high in vitro activity against standard and isolated cultures of bacteria. Highly effective against many aerobic and anaerobic gram-positive and gram-negative microorganisms. In vitro studies confirm high effectiveness of clarithromycin against Legionella pneumophila and Mycoplasma pneumoniae.
The drug is also active against aerobic gram-positive microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Listeria monocytogenes; aerobic gram-negative microorganisms: Haemophilus influenzae, Haemophilus parainftuenzae, Moraxella catarrhalis, Neisseria gonorrhoeae; other microorganisms: Mycoplasma pneumoniae, Chlamydia pneumoniae (TWAR), Chlamydia trachomatis, Mycobacterium leprae, Mycobacterium kansasii, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium avium complex (MAC): Mycobacterium avium, Mycobacferium intracellulare.
The Enterobacteriaceae, Pseudomonas spp. and other non-lactose degrading Gram-negative bacteria are not sensitive to clarithromycin.
The production of b-lactamase has no effect on clarithromycin activity. Most staphylococcal strains that are resistant to methicillin and oxacillin are also resistant to clarithromycin.
Clarithromycin is also effective in vitro against most strains of the following microorganisms (but the safety and effectiveness of clarithromycin in clinical practice has not been confirmed by clinical studies, and the practical significance remains unclear): Aerobic Gram-positive microorganisms: Streptococcus agalactiae, Streptococci (groups C,F,G), Viridans group streptococci; aerobic gram-negative microorganisms: Bordeteila pertussis, Pasteurella multocida; anaerobic gram-positive microorganisms: Clostridium perfringens, Peptococcus niger, Propionibacterium acnes; anaerobic gram-negative microorganisms: Bacteroides melaninogenicus; Borrelia burgdorferi, Treponema pallidum, Campylobacter jejuni.
The microbiological activity of the metabolite is the same as that of the parent substance, or 1-2 times weaker against most microorganisms. The exception is Haemophilus influenzae against which the effectiveness of the metabolite is 2 times higher.
The parent substance and its main metabolite have either additive or synergistic effect against Naemophilus influenzae under in vitro and in vivo conditions depending on the bacterial culture.
The sustained release tablets are a homogeneous crystalline base that allows prolonged release of the active ingredient as it travels through the gastrointestinal tract.
Indications
Active ingredient
Composition
How to take, the dosage
In adults, Clacid SR is prescribed at 500 mg (1 tablet) 1 time per day. In severe infections the dose is increased to 1 g (2 tablets) once a day.
The tablets should be taken with food, swallowed whole without breaking or chewing.
Interaction
Special Instructions
With caution prescribe the drug in patients with liver dysfunction. In the presence of chronic liver disease, regular monitoring of serum enzymes should be carried out.
Patients with mild to moderate renal dysfunction should also be treated with caution. In patients with significant renal impairment (CKR less than 30 ml/min), rapid-release clarithromycin (tablets 250 mg or 500 mg) should be prescribed.
In case of co-administration with warfarin or other indirect anticoagulants, prothrombin time should be monitored.
Synopsis
Contraindications
Side effects
Cardiovascular system disorders: rarely – ventricular arrhythmia, including ventricular tachycardia (with prolongation of the QT interval).
Digestive system disorders: nausea, abdominal pain, vomiting, diarrhea, gastralgia, pancreatitis, glossitis, stomatitis, oral candidiasis, discolored tongue and teeth; rarely – pseudomembranous enterocolitis. Discoloration of teeth is reversible and is usually restored by professional dental cleaning. Rarely, liver dysfunction has been reported, including increased liver enzyme activity, hepatic cellular and/or cholestatic hepatitis with or without jaundice. These liver dysfunctions can be severe, but are usually reversible. Very rare cases of hepatic failure and death have been observed mainly against the background of severe comorbidities and/or concomitant drug therapy.
CNS disorders: transient headaches, dizziness, anxiety, insomnia, nightmares, tinnitus, depersonalization, hallucinations, seizures, feelings of fear; rarely – psychosis, confusion; in some cases – hearing loss (when stopping clarithromycin hearing restored), change of smell (usually accompanied by distortion of taste).
Allergic reactions: urticaria, skin hyperemia, pruritus, anaphylaxis, Stevens-Johnson syndrome.
Hematopoietic system disorders: leukopenia, thrombocytopenia.
Laboratory disorders: increase in blood creatinine; hypoglycemia is rare (with simultaneous use of hypoglycemic agents).
Others: development of microbial resistance.
Overdose
Pregnancy use
Similarities
Weight | 0.030 kg |
---|---|
Shelf life | 1 year |
Conditions of storage | In a light-protected place at 15-30 °C |
Manufacturer | AbbVi S.r.l., Italy |
Medication form | sustained release tablets |
Brand | AbbVi S.r.l. |
Other forms…
Related products
Buy Clacid SR, 500 mg 14 pcs with delivery to USA, UK, Europe and over 120 other countries.